Companies To Watch
-
Companies To Watch: Synlogic
5/31/2019
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
-
Companies To Watch: Provention Bio
5/1/2019
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
-
Companies To Watch: Vyome Therapeutics
4/1/2019
Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.
-
Companies To Watch: Azitra
3/1/2019
Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.
-
Companies-To-Watch 2018 Annual Roundup
3/1/2019
At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.
-
Companies to Watch —Where Are They Now?
2/1/2019
Since launching our Companies To Watch section in 2012 we have covered more than 50 companies. This year we plan to periodically look back at some of them and see where they are today.
-
Companies To Watch: Synspira
1/2/2019
Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”
-
Companies To Watch: Athersys
11/7/2018
Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
-
Companies To Watch: Symbiotix Biotherapies
10/4/2018
Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical-stage development of its lead compound for treating MS and IBD.
-
Companies To Watch: United Neuroscience
9/3/2018
“We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”